- A French cohort study finds that sleep-disordered breathing (SDB) vs no SDB is associated with greater amyloid burden and 3 other biomarkers of Alzheimer disease (AD) in cognitively healthy older adults.
Why this matters
- Results suggest that SDB should be aggressively screened and treated.
- Cross-sectional cohort study of 127 participants (secondary analysis) of the Age-Well clinical trial in France.
- Participants were cognitively healthy older adults who underwent a neuropsychological assessment, polysomnography, MRI, and PET.
- Funding: European Union; Institut National de la Sante et de la Recherche Medicale; others.
- SDB vs no SDB was associated with the following AD biomarkers overlapping the posterior cingulate cortex and precuneus:
- Greater amyloid deposition (t117, 4.51; family-wise error-corrected P=.04; Cohen d, 0.83).
- Greater gray matter volume (t119, 4.12; family-wise error-corrected P=.04; Cohen d, 0.75).
- Greater perfusion (t116, 4.62; family-wise error-corrected P=.001; Cohen d, 0.86).
- Greater glucose metabolism (t79, 4.63; family-wise error-corrected P=.001; Cohen d, 1.04).
- SDB was not associated with cognition, self-reported cognitive and sleep difficulties, or excessive daytime sleepiness symptoms.
- Cross-sectional, observational design.